Identification of novel variant of EML4-ALK fusion gene in NSCLC: Potential benefits of the RT-PCR method

International Journal of Biomedical Science

Volumn 8, Issue 1, 2012, Pages 1-6

  Maus, Martin K H ^a,b   Stephens, Craig ^a   Zeger, Gary ^a,c   Grimminger, Peter P ^b   Huang, Eric ^a  

^a Response Genetics Inc   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ALK inhibitors; EML4 ALK rearrangement; EML4 ALK variants; NSCLC

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RNA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BASE PAIRING; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CELL LINE; DRUG RESISTANCE; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GEL ELECTROPHORESIS; GENE AMPLIFICATION; GENE INSERTION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INTRON; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; ONCOGENE; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION;

ECHINODERMATA;

EID: 84859044774     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 562-565.
2. Sasaaki S, Rodig S, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. European Journal of Cancer. 2010; 46: 1773-1726.
3. Takezawa K, Okamoto I, Nishio K, Jänne PA, et al. Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer. Clinical Cancer Research. 2011; 17: 2140.
4. Kwak EL, Bang YJ, Camidge R. Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 2010; 363: 1694-1428.
5. Sanders HR, Li HR, Bruey J-M, et al. Exon scanning by reverse transcriptase- polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genetics. 2011; 204: 46-51.
6. Choi YL, Takeuchi K, Soda M, et al. Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer. Cancer Research. 2008; 68: 4972-4922.
7. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Molecular Cancer. 2009; 9: 188-190.
8. Takaaki Sasaki T, Koivunen J, Ogino A, et al. A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Cancer Research. 2011; 71: 6051-6060.
9. Solomon B, Varella-Garcia M, Camidge D. ALK Gene Rearrangements A new therapeutic target in an molecularly defined subset of non-small cell lung cancer. Journal of Thoracic Oncology. 2009; 4: 1451.